Detail akcie Corcept Thera online

Business Summary: Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. It is also conducting advanced clinical trials in patients with solid tumors, Amyotrophic Lateral Sclerosis (ALS) and liver disease. It operates through the discovery, development and commercialization of the pharmaceutical products segment. It sells Korlym and a generic version of Korlym in the United States using sales representatives to call on physicians caring for patients with hypercortisolism (Cushing’s syndrome). The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. It sells and distributes Lifyorli in the United States. It is developing its proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Corcept Therapeutics Inc revenues increased 5% to $164.9M. Net loss totaled $31.8M vs. income of $20.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Discovery, development and commercialization of Pharmaceutic segment loss totaling $49.6M vs. income of $3.4M.